AGEN — Agenus Share Price
Last Trade - 00:00- $1.31bn
- $1.19bn
- $84.76m
Momentum
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | |||
| EPS Growth (f) | |||
| Dividend Yield (f) | 1.7% | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | |||
| Price to Tang. Book | |||
| Price to Free Cashflow | |||
| Price to Sales | |||
| EV to EBITDA | |||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | |||
| Return on Equity | |||
| Operating Margin | |||
Financial Summary
| Year End 31st Dec | Unit | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 22.57 | 42.88 | 36.78 | 150.05 | 88.17 | 76.52 | 103.02 | 28.86% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Health trend(F-Score)
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Agenus Inc. (Agenus) is an immuno-oncology (I-O) company. The Company focuses on the discovery and development of therapies that engage the body's immune system to fight cancer. It is developing a I-O portfolio driven by platforms and programs, such as antibody discovery platforms, including Retrocyte Display, SECANT yeast display and phage display technologies designed to produce human antibodies; antibody candidate programs, including checkpoint modulator (CPM) programs; vaccine programs, including Prophage, AutoSynVax and PhosPhoSynVax, and saponin-based vaccine adjuvants, principally QS-21 Stimulon adjuvant (QS-21 Stimulon). The Company's discovery pipeline includes a range of checkpoint modulating (CPM) antibodies. The Company's vaccine platforms include its heat shock protein (HSP)-based Prophage vaccine candidates, and its synthetic vaccine candidates, ASV and PSV.
Directors
- Garo Armen (68)
- Jennifer Buell PRE (46)
- Evan Kearns CCO (40)
- Adam Krauss (48)
- Christine Klaskin VFN (54)
- Steven Oday (60)
- Timothy Wright LED (63)
- Brian Corvese (63)
- Susan Hirsch (68)
- Allison Jeynes-Ellis (55)
- Wadih Jordan (86)
- Ulf Wiinberg (62)
- Last Annual
- December 31st, 2020
- Last Interim
- March 31st, 2021
- Incorporated
- November 10th, 1999
- Public Since
- February 4th, 2000
- No. of Shareholders
- 34,280
- No. of Employees
- 359
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 222,441,009
- Address
- 3 Forbes Rd, LEXINGTON, 02421-7305
- Web
- http://agenusbio.com/
- Phone
- +1 7816744400
- Auditors
- KPMG LLP
Latest News for AGEN
Upcoming events for AGEN
Q3 2021 Agenus Inc Earnings Release
Similar to AGEN
ABEONA THERAPEUTICS ORD
NASDAQ Capital Market
ACASTI PHARMA CL A ORD
NASDAQ Capital Market
ACHIEVE LIFE SCIENCES ORD
NASDAQ Capital Market
ACURX PHARMACEUTICALS ORD
NASDAQ Capital Market
ADDEX THERAPEUTICS ADR
NASDAQ Capital Market
FAQ
As of Today at 19:57 UTC, shares in Agenus are trading at $5.89. This share price information is delayed by 15 minutes.
Shares in Agenus last closed at $5.89 and the price had moved by +47.62% over the past 365 days. In terms of relative price strength the Agenus share price has outperformed the S&P500 Index by +12% over the past year.
The overall consensus recommendation for Agenus is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Agenus does not currently pay a dividend.
Agenus does not currently pay a dividend.
Agenus does not currently pay a dividend.
To buy shares in Agenus you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $5.89, shares in Agenus had a market capitalisation of $1.31bn.
Here are the trading details for Agenus:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: AGEN
Based on an overall assessment of its quality, value and momentum Agenus is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Agenus is $9.00. That is 52.8% above the last closing price of $5.89.
Analysts covering Agenus currently have a consensus Earnings Per Share (EPS) forecast of -$1.03 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Agenus. Over the past six months, its share price has outperformed the S&P500 Index by +16.52%.
As of the last closing price of $5.89, shares in Agenus were trading +46.58% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We are not able to find PE ratio data for Agenus.
Agenus' management team is headed by:
- Garo Armen -
- Jennifer Buell - PRE
- Evan Kearns - CCO
- Adam Krauss -
- Christine Klaskin - VFN
- Steven Oday -
- Timothy Wright - LED
- Brian Corvese -
- Susan Hirsch -
- Allison Jeynes-Ellis -
- Wadih Jordan -
- Ulf Wiinberg -
We do not have data on Agenus' shareholders